Compare Organon & Co. Common Stock (OGN) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Okta, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Okta, Inc. trades at $208.21 (market cap $39.60B). The key difference: Okta, Inc. is far larger — about 10.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Okta, Inc. for 44 Days on average.
| OGN | OKTA | |
|---|---|---|
Market Cap | $3.62B | $39.60B |
Volume | 2,892,999 | 2,315,203 |
Sector | Health | Technology |
52-Week High | $13.81 | $232.13 |
52-Week Low | $5.70 | $62.93 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $11.04B | $37.36B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
OKTA trades at $211.92, down 6.68% today, but maintains strong analyst support with 74% buy ratings and a consensus price target of $201.76. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $0.93. Revenue growth remains robust, climbing from $1.3B in 2022 to $2.6B in 2025, while achieving positive net income of $28M after years of losses. Technical indicators show a bullish trend with key support at $215.
OKTA presents a compelling growth story with improving profitability and strong positioning in identity management. The stock faces valuation concerns with a P/E of 136, but AI security initiatives and consistent earnings beats provide catalysts. Key risks include high valuation multiples and competitive pressures in cybersecurity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
